SCHEMBL10069708

SCHEMBL10069708

CC(C)(C)OC(=O)N1CCC(c2nc(-c3ccc(F)cc3)n[nH]2)CC1

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HPGDS O60760 2/20 0.52
HTT P42858 1/20 0.51
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
PDK2 Q15119 3/20 0.48
JAK2 O60674 1/20 0.47
JAK3 P52333 1/20 0.47
PTK2 Q05397 1/20 0.47
POLB P06746 1/20 0.47
KIT P10721 1/20 0.46
MMP13 P45452 1/20 0.46
ENPP2 Q13822 1/20 0.45
HDAC4 P56524 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
KDM4E B2RXH2 1/20 0.45
MAPT P10636 1/20 0.45
THRB P10828 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10070063 0.89 HTT (0.48) HPGDSHTTMEN1KMT2APOLB
SCHEMBL1653375 0.89 CNR1 (0.53) HPGDSHTTMEN1KMT2APDK2
SCHEMBL1653217 0.89 HPGDS (0.64) HPGDSHTTMEN1KMT2APDK2
SCHEMBL10070506 0.88 HPGDS (0.53) HPGDSHTTMEN1KMT2ASMN1; SMN2
SCHEMBL10070098 0.83 CPT2 (0.51) HPGDSHTTMEN1KMT2ASMN1; SMN2
SCHEMBL12231269 0.83 KIT (0.52) PDK2KITSMN1; SMN2
SCHEMBL10070547 0.82 HPGDS (0.51) HPGDSHTTMEN1KMT2APOLB
SCHEMBL6168833 0.81 HTT (0.51) HPGDSHTTMEN1KMT2AJAK2
SCHEMBL17801068 0.81 HTT (0.47) HPGDSHTTMEN1KMT2AKDM4E
SCHEMBL10070549 0.80 KIT (0.44) HTTPDK2KITKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2308869-B1 AZOLE COMPOUND ASTELLAS PHARMA INC (JP) 2012-09-19 EP disclosed
US-8207199-B2 Azole compound ASTELLAS PHARMA INC. (JP) 2012-06-26 US disclosed
US-20110118311-A1 AZOLE COMPOUND ASTELLAS PHARMA INC. (JP) 2011-05-19 US disclosed
EP-2308869-A1 AZOLE COMPOUND Astellas Pharma Inc. (JP) 2011-04-13 EP disclosed
WO-2010007966-A1 AZOLE COMPOUND アステラス製薬株式会社 (JP) 2010-01-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118311-A1 AZOLE COMPOUND FAAH, FAAH2, TRPV1 HPGDS 1623/4885HTT 3242/4885MEN1 4178/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.